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Purpose of the study
In clinical practice measured drug concentrations often
exhibit significant differences to those published in clini-
cal trials. This can impact on virological efficacy and drug
toxicity. We aimed to describe DRV concentrations
achieved in a cohort of HIV-positive individuals using a
non-standard dose of DRV 900 mg OD with RTV 100 mg
OD.
Methods
HIV-positive patients with no DRV resistance-associated
mutations were commenced on antiretroviral therapy
(ART) regimens with DRV/RTV 900/100 mg OD. Trough
[DRV] (C24)actual and predicted were measured and com-
pared to published protein-corrected (PC)EC50 values for
wild-type (WT) HIV (55 ng/ml) and (PC)EC50
Summary of results
69 patients (pts) commenced OD DRV/RTV and have
reached a median of 23 weeks of therapy (range 4–83;
IQR 12–31); 15 pts started DRV/RTV as their first PI-based
regimen. Others changed for: ART simplification/move to
OD ART (n = 17), GI side-effects (n = 15), low level virae-
mia (n = 6), jaundice (n = 6), lipid abnormalities (n = 6),
perceived potency (n = 4). PI-based regimens changed
from were: LPV/r (n = 25), ATZ/r (n = 20), FAPV/r (n = 2),
double-boosted PI (n = 7). 51 trough [DRV] were
obtained. Twenty-nine pts provided actual trough sam-
ples (23–26.5 hrs post-drug; median = 24 hrs). Median
trough [DRV] was 1,738 ng/ml (range 414–3,582; IQR
1085–2497); this was 31× the PCEC50 for WT HIV. A fur-
ther 22 pts provided blood samples a median of 15 hrs
(range 12.5–21 hrs) post-drug ingestion. Using a t1/2 of
15 hrs the projected C24 was 2026 ng/ml (range 772–
4,558; IQR 1420–2638), representing 37× the PCEC50
for WT HIV. Furthermore 50/51 samples were above the
PCEC50 for Res HIV. No patients have exhibited virologi-
cal failure to date. All six swapping for low level viraemia
reached an HIV viral load of <40 copies/ml. There was no
incidence of rash and only one grade 1 LFT abnormality.
Multivariate analysis of factors affecting DRV concentra-
tions, and metabolic parameters, will be presented.
Conclusion
Once-daily darunavir used in routine clinical care pro-
duces trough DRV drug concentrations in excess of 30×
the PCEC50 for WT HIV. This is in keeping with data from
randomised controlled trials.
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